Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data

Background We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology. Methods Population-based cancer registry data on 72,217 women diagnosed wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 2020-09, Vol.123 (5), p.852-859
Hauptverfasser: Mesa-Eguiagaray, Ines, Wild, Sarah H., Rosenberg, Philip S., Bird, Sheila M., Brewster, David H., Hall, Peter S., Cameron, David A., Morrison, David, Figueroa, Jonine D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 859
container_issue 5
container_start_page 852
container_title British journal of cancer
container_volume 123
creator Mesa-Eguiagaray, Ines
Wild, Sarah H.
Rosenberg, Philip S.
Bird, Sheila M.
Brewster, David H.
Hall, Peter S.
Cameron, David A.
Morrison, David
Figueroa, Jonine D.
description Background We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology. Methods Population-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Joinpoint regression and age–period–cohort models were used to assess whether significant differences were observed in incidence trends by ER status. Results Overall, ER-positive tumour incidence increased by 0.4%/year (95% confidence interval (CI): −0.1, 1.0). Among routinely screened women aged 50–69 years, we observed an increase in ASR from 1997 to 2011 (1.6%/year, 95% CI: 1.2–2.1). ER-negative tumour incidence decreased among all ages by 2.5%/year (95% CI: −3.9 to −1.1%) over the study period. Compared with the 1941–1959 birth cohort, women born in 1912–1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born in 1960–1986 had lower IRR for ER− tumours. Conclusions Future incidence and survival reporting should be monitored by molecular subtypes to inform clinical planning and cancer control programmes.
doi_str_mv 10.1038/s41416-020-0938-z
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_2475028341</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475028341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-1ddbc7867f48f4677602d604aed8673dd2db4ce909ac5b77933122b0cfaf66aa3</originalsourceid><addsrcrecordid>eNqNkkuLFDEQxxtR3HH1A3iRgBdBWvPqTtqDIOMTFjyo55BO0rNZupM2SSu9H8TPa42zOz5AMZdUqn5VVFX-VXWf4CcEM_k0c8JJW2OKa9wxWV_eqDakYbQmkoqb1QZjLCBC8Ul1J-cLeHZYitvVCaMNHMY31beXPhcfTEHFTXNMekQluWAz8gH1yelckNHBuAQO460DEw0pToh0nUAlIopJi_oVTXF0Zhl1Qnnpyzq7_AxpNMcZfMXHUPc6O4tyWeyK4oA-mFiKz-fX5ZPbQStpRVYXfbe6Negxu3tX92n16fWrj9u39dn7N--2L85qwztZamJtb4RsxcDlwFshWkxti7l2FpzMWmp7blyHO22aXoiOMUJpj82gh7bVmp1Wzw9156WfnDUuFFiBmpOfdFpV1F79Hgn-XO3iFyV4C0ukUODRVYEUPy8uFzX5bNw46uDikhXlpKGdZAwD-vAP9CIuKcB4QIkGU8k4-TfFOiIbwlqgyIEyKeac3HBsmWC114Y6aEOBNtReG-oSch78Ousx41oMAMgD8NX1ccjG7z_7iIF6Gk5IxxqwMNn68uNbt3EJBVIf_38q0PRAZyDCzqWfM_69_e_ibeca</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2439185136</pqid></control><display><type>article</type><title>Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Web of Science - Science Citation Index Expanded - 2020&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>PubMed Central</source><creator>Mesa-Eguiagaray, Ines ; Wild, Sarah H. ; Rosenberg, Philip S. ; Bird, Sheila M. ; Brewster, David H. ; Hall, Peter S. ; Cameron, David A. ; Morrison, David ; Figueroa, Jonine D.</creator><creatorcontrib>Mesa-Eguiagaray, Ines ; Wild, Sarah H. ; Rosenberg, Philip S. ; Bird, Sheila M. ; Brewster, David H. ; Hall, Peter S. ; Cameron, David A. ; Morrison, David ; Figueroa, Jonine D.</creatorcontrib><description>Background We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology. Methods Population-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Joinpoint regression and age–period–cohort models were used to assess whether significant differences were observed in incidence trends by ER status. Results Overall, ER-positive tumour incidence increased by 0.4%/year (95% confidence interval (CI): −0.1, 1.0). Among routinely screened women aged 50–69 years, we observed an increase in ASR from 1997 to 2011 (1.6%/year, 95% CI: 1.2–2.1). ER-negative tumour incidence decreased among all ages by 2.5%/year (95% CI: −3.9 to −1.1%) over the study period. Compared with the 1941–1959 birth cohort, women born in 1912–1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born in 1960–1986 had lower IRR for ER− tumours. Conclusions Future incidence and survival reporting should be monitored by molecular subtypes to inform clinical planning and cancer control programmes.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-020-0938-z</identifier><identifier>PMID: 32555534</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1857 ; 692/4028/67/2324 ; Age ; Age Factors ; Aged ; Biomedical and Life Sciences ; Biomedicine ; Breast cancer ; Breast Neoplasms - epidemiology ; Breast Neoplasms - metabolism ; Cancer Research ; Cohort Studies ; Drug Resistance ; Epidemiology ; Female ; Humans ; Incidence ; Life Sciences &amp; Biomedicine ; Middle Aged ; Molecular Medicine ; Oncology ; Population studies ; Population-based studies ; Public health ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Registries ; Regression analysis ; Science &amp; Technology ; Scotland - epidemiology ; Trends ; Tumors</subject><ispartof>British journal of cancer, 2020-09, Vol.123 (5), p.852-859</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>32</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000541193500001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c498t-1ddbc7867f48f4677602d604aed8673dd2db4ce909ac5b77933122b0cfaf66aa3</citedby><cites>FETCH-LOGICAL-c498t-1ddbc7867f48f4677602d604aed8673dd2db4ce909ac5b77933122b0cfaf66aa3</cites><orcidid>0000-0001-6015-7841 ; 0000-0002-5346-5608 ; 0000-0002-5100-623X ; 0000-0002-2717-7979</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463252/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463252/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,887,27931,27932,28255,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32555534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mesa-Eguiagaray, Ines</creatorcontrib><creatorcontrib>Wild, Sarah H.</creatorcontrib><creatorcontrib>Rosenberg, Philip S.</creatorcontrib><creatorcontrib>Bird, Sheila M.</creatorcontrib><creatorcontrib>Brewster, David H.</creatorcontrib><creatorcontrib>Hall, Peter S.</creatorcontrib><creatorcontrib>Cameron, David A.</creatorcontrib><creatorcontrib>Morrison, David</creatorcontrib><creatorcontrib>Figueroa, Jonine D.</creatorcontrib><title>Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>BRIT J CANCER</addtitle><addtitle>Br J Cancer</addtitle><description>Background We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology. Methods Population-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Joinpoint regression and age–period–cohort models were used to assess whether significant differences were observed in incidence trends by ER status. Results Overall, ER-positive tumour incidence increased by 0.4%/year (95% confidence interval (CI): −0.1, 1.0). Among routinely screened women aged 50–69 years, we observed an increase in ASR from 1997 to 2011 (1.6%/year, 95% CI: 1.2–2.1). ER-negative tumour incidence decreased among all ages by 2.5%/year (95% CI: −3.9 to −1.1%) over the study period. Compared with the 1941–1959 birth cohort, women born in 1912–1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born in 1960–1986 had lower IRR for ER− tumours. Conclusions Future incidence and survival reporting should be monitored by molecular subtypes to inform clinical planning and cancer control programmes.</description><subject>631/67/1857</subject><subject>692/4028/67/2324</subject><subject>Age</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - metabolism</subject><subject>Cancer Research</subject><subject>Cohort Studies</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Public health</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Registries</subject><subject>Regression analysis</subject><subject>Science &amp; Technology</subject><subject>Scotland - epidemiology</subject><subject>Trends</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkkuLFDEQxxtR3HH1A3iRgBdBWvPqTtqDIOMTFjyo55BO0rNZupM2SSu9H8TPa42zOz5AMZdUqn5VVFX-VXWf4CcEM_k0c8JJW2OKa9wxWV_eqDakYbQmkoqb1QZjLCBC8Ul1J-cLeHZYitvVCaMNHMY31beXPhcfTEHFTXNMekQluWAz8gH1yelckNHBuAQO460DEw0pToh0nUAlIopJi_oVTXF0Zhl1Qnnpyzq7_AxpNMcZfMXHUPc6O4tyWeyK4oA-mFiKz-fX5ZPbQStpRVYXfbe6Negxu3tX92n16fWrj9u39dn7N--2L85qwztZamJtb4RsxcDlwFshWkxti7l2FpzMWmp7blyHO22aXoiOMUJpj82gh7bVmp1Wzw9156WfnDUuFFiBmpOfdFpV1F79Hgn-XO3iFyV4C0ukUODRVYEUPy8uFzX5bNw46uDikhXlpKGdZAwD-vAP9CIuKcB4QIkGU8k4-TfFOiIbwlqgyIEyKeac3HBsmWC114Y6aEOBNtReG-oSch78Ousx41oMAMgD8NX1ccjG7z_7iIF6Gk5IxxqwMNn68uNbt3EJBVIf_38q0PRAZyDCzqWfM_69_e_ibeca</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Mesa-Eguiagaray, Ines</creator><creator>Wild, Sarah H.</creator><creator>Rosenberg, Philip S.</creator><creator>Bird, Sheila M.</creator><creator>Brewster, David H.</creator><creator>Hall, Peter S.</creator><creator>Cameron, David A.</creator><creator>Morrison, David</creator><creator>Figueroa, Jonine D.</creator><general>Nature Publishing Group UK</general><general>Springer Nature</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6015-7841</orcidid><orcidid>https://orcid.org/0000-0002-5346-5608</orcidid><orcidid>https://orcid.org/0000-0002-5100-623X</orcidid><orcidid>https://orcid.org/0000-0002-2717-7979</orcidid></search><sort><creationdate>20200901</creationdate><title>Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data</title><author>Mesa-Eguiagaray, Ines ; Wild, Sarah H. ; Rosenberg, Philip S. ; Bird, Sheila M. ; Brewster, David H. ; Hall, Peter S. ; Cameron, David A. ; Morrison, David ; Figueroa, Jonine D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-1ddbc7867f48f4677602d604aed8673dd2db4ce909ac5b77933122b0cfaf66aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/67/1857</topic><topic>692/4028/67/2324</topic><topic>Age</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - metabolism</topic><topic>Cancer Research</topic><topic>Cohort Studies</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Public health</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Registries</topic><topic>Regression analysis</topic><topic>Science &amp; Technology</topic><topic>Scotland - epidemiology</topic><topic>Trends</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mesa-Eguiagaray, Ines</creatorcontrib><creatorcontrib>Wild, Sarah H.</creatorcontrib><creatorcontrib>Rosenberg, Philip S.</creatorcontrib><creatorcontrib>Bird, Sheila M.</creatorcontrib><creatorcontrib>Brewster, David H.</creatorcontrib><creatorcontrib>Hall, Peter S.</creatorcontrib><creatorcontrib>Cameron, David A.</creatorcontrib><creatorcontrib>Morrison, David</creatorcontrib><creatorcontrib>Figueroa, Jonine D.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mesa-Eguiagaray, Ines</au><au>Wild, Sarah H.</au><au>Rosenberg, Philip S.</au><au>Bird, Sheila M.</au><au>Brewster, David H.</au><au>Hall, Peter S.</au><au>Cameron, David A.</au><au>Morrison, David</au><au>Figueroa, Jonine D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><stitle>BRIT J CANCER</stitle><addtitle>Br J Cancer</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>123</volume><issue>5</issue><spage>852</spage><epage>859</epage><pages>852-859</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Background We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology. Methods Population-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to 2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the 8% of missing oestrogen receptor (ER) status. Joinpoint regression and age–period–cohort models were used to assess whether significant differences were observed in incidence trends by ER status. Results Overall, ER-positive tumour incidence increased by 0.4%/year (95% confidence interval (CI): −0.1, 1.0). Among routinely screened women aged 50–69 years, we observed an increase in ASR from 1997 to 2011 (1.6%/year, 95% CI: 1.2–2.1). ER-negative tumour incidence decreased among all ages by 2.5%/year (95% CI: −3.9 to −1.1%) over the study period. Compared with the 1941–1959 birth cohort, women born in 1912–1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born in 1960–1986 had lower IRR for ER− tumours. Conclusions Future incidence and survival reporting should be monitored by molecular subtypes to inform clinical planning and cancer control programmes.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32555534</pmid><doi>10.1038/s41416-020-0938-z</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6015-7841</orcidid><orcidid>https://orcid.org/0000-0002-5346-5608</orcidid><orcidid>https://orcid.org/0000-0002-5100-623X</orcidid><orcidid>https://orcid.org/0000-0002-2717-7979</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 2020-09, Vol.123 (5), p.852-859
issn 0007-0920
1532-1827
language eng
recordid cdi_proquest_journals_2475028341
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central
subjects 631/67/1857
692/4028/67/2324
Age
Age Factors
Aged
Biomedical and Life Sciences
Biomedicine
Breast cancer
Breast Neoplasms - epidemiology
Breast Neoplasms - metabolism
Cancer Research
Cohort Studies
Drug Resistance
Epidemiology
Female
Humans
Incidence
Life Sciences & Biomedicine
Middle Aged
Molecular Medicine
Oncology
Population studies
Population-based studies
Public health
Receptor, ErbB-2 - metabolism
Receptors, Estrogen - metabolism
Registries
Regression analysis
Science & Technology
Scotland - epidemiology
Trends
Tumors
title Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T06%3A43%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinct%20temporal%20trends%20in%20breast%20cancer%20incidence%20from%201997%20to%202016%20by%20molecular%20subtypes:%20a%20population-based%20study%20of%20Scottish%20cancer%20registry%20data&rft.jtitle=British%20journal%20of%20cancer&rft.au=Mesa-Eguiagaray,%20Ines&rft.date=2020-09-01&rft.volume=123&rft.issue=5&rft.spage=852&rft.epage=859&rft.pages=852-859&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-020-0938-z&rft_dat=%3Cproquest_pubme%3E2475028341%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2439185136&rft_id=info:pmid/32555534&rfr_iscdi=true